COVID-19: Publikationen

Management

Guidelines for therapy of patients with chronic myeloproliferative neoplasms during the novel coronavirus SARS-CoV2 pandemic.
Evaluation of COVID 19 infection in 279 cancer patients treated during a 90-day period in 2020 pandemic.
Prevalence of COVID-19 diagnosis in Dutch CML patients during the 2020 SARS-CoV2 pandemic. A prospective cohort study.
How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey.
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey.
Regional BCG vaccination policy in former East- and West Germany may impact on both severity of SARS-CoV-2 and incidence of childhood leukemia.
Risk factors for death in 1859 subjects with COVID-19.
Rewriting the rules for care of MDS and AML patients in the time of COVID-19
Optimal Management of Acute Lymphoblastic Leukemia (ALL) in Adult Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic
Frequently Asked Questions Regarding SARS-CoV-2 in Cancer Patients-Recommendations for Clinicians Caring for Patients With Malignant Diseases
Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation
Management of hematologic disease under the COVID-19 pandemic: experience from China
ILROG Emergency Guidelines for Radiation Therapy of Hematological Malignancies During the COVID-19 Pandemic
Treating Leukemia in the Time of COVID-19
Risk of COVID-19 for patients with cancer
Managing COVID-19 in the oncology clinic and avoiding the distraction effect
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists’ perspective
Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic
Hematology in the time of COVID-19
Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic
Oncology Practice During the COVID-19 Pandemic
Acute leukemia in the time of COVID-19

Fallberichte

Clinical characteristics and outcome of SARS-CoV-2-infected patients with haematological diseases: a retrospective case study in four hospitals in Italy, Spain and the Netherlands.
Clinical characteristics of four cancer patients with SARS-CoV-2 infection in Wuhan, China.
Clinical Characteristics of Hematological Patients Concomitant with COVID-19.
Impact of Covid-19 on the treatment of acute myeloid leukemia.
Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
Confirmed Coronavirus Disease-19 (COVID-19) in a Male with Chronic Myeloid Leukemia Complicated by Febrile Neutropenia and Acute Respiratory Distress Syndrome.
Atypical Imaging Findings in Leukemia With SARS-CoV-2 Infection
SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection
Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies
Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia
COVID-19 in persons with chronic myeloid leukaemia
COVID-19 in persons with haematological cancers
Response to "COVID-19 in persons with haematological cancers"
Reply to “COVID-19 in persons with haematological cancers”: a focus on myeloid neoplasms and risk factors for mortality

Behandlung und Mechanismus

Effect of hydroxychloroquine on COVID-19 prevention in cancer patients undergoing treatment: a structured summary of a study protocol for a randomised controlled trial.
Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation
Poor outcome in patients with acute leukemia on intensive chemotherapy and COVID-19
SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19
Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis
Cancer Patients in SARS-CoV-2 Infection: A Nationwide Analysis in China
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
Hematological features of persons with COVID-19
Lower Antibodies Rate in Cancer Patients After Symptomatic COVID-19 Than In Healthcare Workers

Pädiatrische Patienten

Clinical characteristics and outcome of SARS-CoV-2 infection in Italian pediatric oncology patients: a study from the Infectious Diseases Working Group of the AIEOP.
SARS-CoV-2 infection in a neutropenic pediatric patient with leukemia: Addressing the need for universal guidelines for treatment of SARS-CoV-2-positive, immunocompromised patients.
COVID-19 and childhood acute lymphoblastic leukemia
COVID-19 and acute lymphoblastic leukemias of children and adolescents: First recommendations of the Leukemia committee of the French Society for the fight against Cancers and Leukemias in children and adolescents (SFCE)
FIRST CASE OF CORONAVIRUS DISEASE 2019 IN CHILDHOOD LEUKEMIA IN CHINA
Clinical Strategies for Treating Pediatric Cancer During the Outbreak of 2019 Novel Coronavirus Infection
Challenges posed by COVID-19 to children with cancer